Searchable abstracts of presentations at key conferences in endocrinology

ea0021cm1.3 | Long-term consequences of endocrine diseases | SFEBES2009

Long term consequences of Cushing's syndrome

Webb Susan , Resmini E , Barahona M J , Santos A , Ybarra J

Endogenous hypercortisolism and chronic glucocorticoid (GC) therapy reduce bone mass, increase central fat mass, alter adipokines and enhance cardiovascular risk. Surgery (pituitary, adrenal or for ectopic ACTH) can control hypercortisolism in 90% of patients in experienced hands, and is often followed by inhibition of the adrenal axis, requiring substitution therapy with GC for months or years. We have been interested in learning on long-term outcome of ‘cured’ CS p...

ea0022p621 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Decreased cortical thickness on MRI in patients with Cushing's syndrome: preliminary experience

Santos Alicia , Granell Esther , Resmini Eugenia , Ybarra Juan , Portella Maria J , Perez Victor , Barahona Maria J , Mourelo Olga Lopez , Vives Yolanda , De Juan Manuel , Pires Patricia , Gomez Anson Beatriz , Webb Susan

Introduction: Patients with Cushing’s syndrome might present a variety of brain alterations. There is however little evidence from MRI studies demonstrating atrophy of either frontal or medial temporal brain regions.Aims: To study cortical alterations (decreased cortical thickness) on MRI in patients with Cushing’s syndrome (CS), as compared to controls (C), and long-standing major depressive disorder (MDD).Material and m...